BioSpace News Archive

Antibodies have the Potential to Effectively Target Several Stages of the Disease with Evident Benefits at a Patient Level and a Systemic Level, According to a New White Paper by Trinity Life Sciences

The global market for automated endoscope reprocessors market is growing at a stellar rate and is likely to continue during the forecast period 2018 – 2028, owing to aggressive growth in the healthcare sector.

Masimo announced the findings of a study published in the Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d’Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.

Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer, announces that Richard Slansky is appointed as Chief Financial Officer and proposes Anthony Marucci as independent member of the Board of Directors.

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye Confirms that untreated ND4 LHON patients have the worst visual outcomes The natural history of ND4 LHON disease is characterized by severe and permanent deterioration of BCVA

DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A., a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2021.

Camurus AB announced that the Australian regulatory agency, the Therapeutic Goods Administration, has approved key label updates to Buvidal® Weekly and Buvidal® Monthly modified-release solutions for injection.

Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021.

OneOncology, the national platform for independent community oncology practices, announced that Natalie Dickson, MD, President and Chief Medical Officer for Tennessee Oncology, and Curtis Warfield, President and Chief Executive Officer of Windham Advisors, a private equity and strategic advisory firm, have joined the Board of Managers.